• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / North American / The United States / FDA / SaneVax Letter to Dr. Margaret Hamburg, FDA Commissioner

SaneVax Letter to Dr. Margaret Hamburg, FDA Commissioner

April 27, 2011 By admin Leave a Comment

April 22, 2011

Dear Dr. Hamburg:

I have just read a press release issued by Roche announcing the FDA approval of its cobas HPV Test. The press release states “The cobas HPV Test is the only FDA-approved cervical cancer screening test that allows HPV 16 and 18 genotyping concurrently with high-risk HPV testing.”

It is disturbing that the FDA has approved this class III cancer screening test without an open Advisory committee meeting. As a result, the public does not know what safety and efficacy data was submitted to the FDA in Roche’s PMA application. I assume the pivotal data for the application are contained in the following publication by Stoler et al.

Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011 Mar;135(3):468-75.

If my assumption is correct, the approval of the cobas HPV Test for HPV 16 and 18 genotyping is contrary to the FDA Draft Guidance for Industry and FDA Staff – Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses, a document issued on, September 9, 2009. This document contains the following important statements:

(1) HPV vaccination and study populations 

Due to the likelihood of an increase in the number of HPV vaccinated individuals in the United States over the coming years, the most clinically relevant HPV genotypes are expected to shift over time. For this reason, you should consider including in your analytical evaluations (precision, carryover, stability, etc.), one of the most clinically relevant non-vaccine targeted HPV genotypes (such as HPV 45 or 31) in addition to HPV genotypes targeted by any current FDA licensed vaccine(s).

(2)Evaluation of HPV detection in clinical dataset 

We recommend that you provide an evaluation of your device’s ability to detect the targeted HPV genotypes in your clinical dataset. One way to do this is to perform an FDA-approved HPV test that detects the same genotypes as your test, or you may perform PCR plus sequencing (PCR/Sequencing) on your clinical specimens and compare these results to the results of your device. Use of a composite HPV comparator that incorporates both FDA-approved HPV test(s) and/or PCR/Sequencing is also an option…….A comparison against PCR followed by sequencing of the amplicon is especially important for HPV genotyping assays to establish that the correct HPV genotype has been identified by your device.

Since the cobas HPV Test for HPV 16 and 18 genotyping has not been validated by an FDA-approved genotyping HPV test, or by PCR plus sequencing, this test will be potentially misused as a valid HPV genotyping method for vaccination monitoring.

Therefore, the SaneVax Team hereby respectfully requests that the FDA rescind its approval of the cobas HPV Test for HPV 16 and 18 genotyping for safe and effective HPV vaccination, until such time as validation occurs.

We also object to the approval of this HPV Test as a cervical cancer screening device because the published data do not support such a claim. The data only deal with the presence or absence of HPV in ASCUS patients and their correlation with CIN2 and CIN3 lesions.

The positive predictive value (ppv) of this cancer test for CIN3 (8.4%) was reported to be lower than the ppv for CIN2 lesions (14.0%). We all know a CIN3 lesion is more cancer-like than a CIN2 lesion. It is highly disturbing to learn that a ‘cancer test’ approved by the FDA appears to lose its positive predictive value as a precancerous lesion progresses to a more severe stage closer to cancer.

With all due respect, according to the information above, this test appears to be nothing more than an HPV detection test for use in precancerous lesions, which quite frequently reverse on their own without proceeding to the development of cancer. The declining positive predictive value hardly inspires confidence in a ‘cancer screening’ test.

Signed on behalf of the SaneVax Board of Directors,
 
Norma Erickson, President
SaneVax Inc.

Related

Filed Under: FDA, HPV Science Tagged With: cervical cancer screening test, cobas HPV test, FDA, Roche

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Amy From Indiana

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Path’s HPV Trials in India: Troubling Questions

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in